Clinical Trials Browser

Completed × dalotuzumab × Breast × Clear all

NCT01605396 2019-03-25

MK-8669-064

Phase 2 Completed

80 enrolled 13 charts

Breast Neoplasms

NCT00759785 2018-08-15

MK-0646-013

Phase 1 Completed

48 enrolled 10 charts

Breast Neoplasms

NCT01220570 2015-01-21

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

Phase 1 Completed

Breast Neoplasms